Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008)

Cancer Immunology, Immunotherapy

Volumn 64, Issue 4, 2015, Pages 437-446

  Lacouture, Mario E ^a   Morris, John C ^b   Lawrence, Donald P ^c   Tan, Antoinette R ^d   Olencki, Thomas E ^e   Shapiro, Geoffrey I ^f   Dezube, Bruce J ^g   Berzofsky, Jay A ^b   Hsu, Frank J ^h   Guitart, Joan ⁱ  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^h GENZYME CORPORATION   (United States)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Fresolimumab; GC1008; Keratoacanthoma; Squamous cell cancer; Transforming growth factor

Indexed keywords

CD99 ANTIGEN; FRESOLIMUMAB; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA; MONOCLONAL ANTIBODY; TP53 PROTEIN, HUMAN; TUMOR MARKER;

AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GENE OVEREXPRESSION; HERPES ZOSTER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERKERATOSIS; IN SITU HYBRIDIZATION; KERATOACANTHOMA; PATIENT CARE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN BIOPSY; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION; WART VIRUS; ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; SKIN; SKIN NEOPLASMS;

ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; HUMANS; KERATOACANTHOMA; KI-67 ANTIGEN; SKIN; SKIN NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84925536864     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1653-0     Document Type: Article

References (32)

1. Roberts AB, Anzano MA, Lamb LC, Smith JM, Sporn MB (1981) New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. Proc Natl Acad Sci USA 78(9):5339–5343
2. Massague J (2008) TGFbeta in cancer. Cell 134(2):215–230
3. Tan AR, Alexe G, Reiss M (2009) Transforming growth factor-beta signaling: Emerging stem cell target in metastatic breast cancer? Breast Cancer Res Treat 115(3):453–495
4. Wrzesinski SH, Wan YY, Flavell RA (2007) Transforming growth factor-beta and the immune response: implications for anticancer therapy. Clin Cancer Res 13(18 Pt 1):5262–5270
5. Morris JC, Shapiro GI, Tan AR, Lawrence DP, Olenki TE, Dezube BJ, Hsu FJ, Reiss M, Berzofsky JA (2008) Phase I/II Study of GC1008: a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC). J Clin Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 26, no 15S (May 20 Supplement): 9028
6. Morris JC, Tan AR, Olencki TE, Shapiro GI, Dezube BJ, Reiss M, Hsu FJ, Berzofsky JA, Lawrence DP (2014) Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFbeta) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS One 9(3):e90353
7. Shirakata Y (2010) Regulation of epidermal keratinocytes by growth factors. J Dermatol Sci 59(2):73–80
8. Zhang YE (2009) Non-smad pathways in TGF-beta signaling. Cell Res 19(1):128–139
9. Arnault JP, Wechsler J, Escudier B, Spatz A, Tomasic G, Sibaud V, Aractingi S, Grange JD, Poirier-Colame V, Malka D, Soria JC, Mateus C, Robert C (2009) Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 27(23):e59–e61
10. Arnault JP, Mateus C, Escudier B, Tomasic G, Wechsler J, Hollville E, Soria JC, Malka D, Sarasin A, Larcher M, Andre J, Kamsu-Kom N, Boussemart L, Lacroix L, Spatz A, Eggermont AM, Druillennec S, Vagner S, Eychene A, Dumaz N, Robert C (2012) Skin tumors induced by sorafenib; paradoxic RAS–RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res 18(1):263–272
11. Esser AC, Abril A, Fayne S, Doyle JA (2004) Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab. J Am Acad Dermatol 50(5 Suppl):S75–S77
12. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O’Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516
13. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S, Kee D, Ma Y, Zhang C, Habets G, Burton EA, Wong B, Nguyen H, Kockx M, Andries L, Lestini B, Nolop KB, Lee RJ, Joe AK, Troy JL, Gonzalez R, Hutson TE, Puzanov I, Chmielowski B, Springer CJ, McArthur GA, Sosman JA, Lo RS, Ribas A, Marais R (2012) RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366(3):207–215
14. Kefford R, Arkenau H, Brown MP, Millward M, Infante JR, Long GV, Ouellet D, Curtis M, Lebowitz PF, Falchook GS (2010) Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. ASCO Annual Meeting, J Clin Oncol, 28:15s, (suppl; abstr 8503)
15. Anforth RM, Blumetti TC, Kefford RF, Sharma R, Scolyer RA, Kossard S, Long GV, Fernandez-Penas P (2012) Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol 167(5):1153–1160
16. Suk JD, Park WS, Kim DK (2009) Low rates of somatic p53 mutations in keratoacanthomas. J Dermatol Sci 53(1):72–73
17. Batinac T, Zamolo G, Coklo M, Hadzisejdic I, Stemberger C, Zauhar G (2006) Expression of cell cycle and apoptosis regulatory proteins in keratoacanthoma and squamous cell carcinoma. Pathol Res Pract 202(8):599–607
18. Sakiz D, Turkmenoglu TT, Kabukcuoglu F (2009) The expression of p63 and p53 in keratoacanthoma and intraepidermal and invasive neoplasms of the skin. Pathol Res Pract 205(9):589–594
19. Kanner WA, Brill LB 2nd, Patterson JW, Wick MR (2010) CD10, p63 and CD99 expression in the differential diagnosis of atypical fibroxanthoma, spindle cell squamous cell carcinoma and desmoplastic melanoma. J Cutan Pathol 37(7):744–750
20. Karaa A, Khachemoune A (2007) Keratoacanthoma: a tumor in search of a classification. Int J Dermatol 46(7):671–678
21. Putti TC, Teh M, Lee YS (2004) Biological behavior of keratoacanthoma and squamous cell carcinoma: telomerase activity and COX-2 as potential markers. Mod Pathol 17(4):468–475
22. Ko CJ (2010) Keratoacanthoma: facts and controversies. Clin Dermatol 28(3):254–261
23. Schwartz RA (1994) Keratoacanthoma. J Am Acad Dermatol 30(1):1–19
24. Kossard S, Tan KB, Choy C (2008) Keratoacanthoma and infundibulocystic squamous cell carcinoma. Am J Dermatopathol 30(2):127–134
25. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM, Karlsson S (1993) Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 90(2):770–774
26. Yaswen L, Kulkarni AB, Fredrickson T, Mittleman B, Schiffman R, Payne S, Longenecker G, Mozes E, Karlsson S (1996) Autoimmune manifestations in the transforming growth factor-beta 1 knockout mouse. Blood 87(4):1439–1445
27. Vitsky A, Waire J, Pawliuk R, Bond A, Matthews D, Lacasse E, Hawes ML, Nelson C, Richards S, Piepenhagen PA, Garman RD, Andrews L, Thurberg BL, Lonning S, Ledbetter S, Ruzek MC (2009) Homeostatic role of transforming growth factor-beta in the oral cavity and esophagus of mice and its expression by mast cells in these tissues. Am J Pathol 174(6):2137–2149
28. Mordasky Markell L, Perez-Lorenzo R, Masiuk KE, Kennett MJ, Glick AB (2010) Use of a TGFbeta type I receptor inhibitor in mouse skin carcinogenesis reveals a dual role for TGFbeta signaling in tumor promotion and progression. Carcinogenesis 31(12):2127–2135
29. Davies M, Prime SS, Eveson JW, Price N, Ganapathy A, D’Mello A, Paterson IC (2012) Transforming growth factor-beta enhances invasion and metastasis in RAS-transfected human malignant epidermal keratinocytes. Int J Exp Pathol 93(2):148–156
30. Goudie DR, D’Alessandro M, Merriman B, Lee H, Szeverenyi I, Avery S, O’Connor BD, Nelson SF, Coats SE, Stewart A, Christie L, Pichert G, Friedel J, Hayes I, Burrows N, Whittaker S, Gerdes AM, Broesby-Olsen S, Ferguson-Smith MA, Verma C, Lunny DP, Reversade B, Lane EB (2011) Multiple self-healing squamous epithelioma is caused by a disease-specific spectrum of mutations in TGFBR1. Nat Genet 43(4):365–369
31. Oberholzer PA, Kee D, Dziunycz P, Sucker A, Kamsukom N, Jones R, Roden C, Chalk CJ, Ardlie K, Palescandolo E, Piris A, MacConaill LE, Robert C, Hofbauer GF, McArthur GA, Schadendorf D, Garraway LA (2012) RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 30(3):316–321
32. Hodak E, Jones RE, Ackerman AB (1993) Solitary keratoacanthoma is a squamous-cell carcinoma: three examples with metastases. Am J Dermatopathol 15(4):332–342